Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Revenues up 5%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb

1Q Revenues: $5.3 billion (+5%)

1Q Earnings: $1.1 billion (+12%)

Comments: U.S. sales increased 6% to $3.5 billion in the quarter. International sales increased 2% to $1.8 billion. Growth in the quarter was led by Yervoy, which had sales of $154.0 million, Onglyza/Kombiglyze, up 99% to $161.0 million, Sprycel, up 34% to $231.0 million, Orencia, up 28% to $254 million, and Baraclude, up 18% to $325.0 million. R&D expenses decreased 3% to $909.0 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters